FMP
TransCode Therapeutics, Inc.
RNAZ
NASDAQ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
0.273 USD
-0.0841 (-30.86%)
RNAZ Financial Statements
Year
2024
2023
2022
2021
Total Revenue
0
0
0
0
Cost of Revenue
0
516.75k
98.61k
42.47k
Gross Profit
0
-516.75k
-98.61k
-42.47k
Operating Expenses
15.66B
19.42M
17.59M
5.87M
Research and Development
9.71B
12.26M
10.23M
2.75M
Selling, General & Administrative Expenses
5.95B
6.64M
8.43M
3.4M
Selling & Marketing Expenses
0
-7.15B
0
0
General & Administrative Expenses
5.95B
7.15B
8.43M
3.4M
Other Expenses
0
0
-1.08M
-278.33k
Operating Income
0
-19.42M
-18.67M
-6.15M
Total Other Income/Expenses Net
0
872.42k
1.1M
-692.26k
Income Before Tax
-16.79B
-18.55M
-17.56M
-6.84M
Income Tax
0
0
17.56M
95.07k
Net Income
-16.79B
-18.55M
-35.13M
-6.94M
Basic EPS
-47.14
-103.61
-2.2k
-658.8
EPS Diluted
-47.14
-103.61
-2.17k
-658.8
Basic Average Shares
356.12M
179k
16k
10.53k
Diluted Average Shares
356.12M
179.01k
16.22k
10.53k
EBITDA
0
-17.97M
-17.47M
-6.11M
All figures are in USD.
